Cotrimoxazole inhibits dhfr and dhps and reportedly selects for drug resistance in pathogens. Here, Streptococcus mutans isolates were obtained from saliva of HIV/AIDS patients taking cotrimoxazole prophylaxis in Uganda. The isolates were tested for resistance to cotrimoxazole and their folP DNA (which encodes sulfonamide-targeted enzyme dhps) cloned in pUC19. A set of recombinant plasmids carrying different point mutations in cloned folP were separately transformed into folP-deficient Escherichia coli. Using sulfonamide-containing media, we assessed the growth of folP-deficient bacteria harbouring plasmids with differing folP point mutations. Interestingly, cloned folP with three mutations (A37V, N172D, R193Q) derived from Streptococcus mutans 8 conferred substantial resistance against sulfonamide to folP-deficient bacteria. Indeed, change of any of the three residues (A37V, N172D, and R193Q) in plasmid-encoded folP diminished the bacterial resistance to sulfonamide while removal of all three mutations abolished the resistance. In contrast, plasmids carrying four other mutations (A46V, E80K, Q122H, and S146G) in folP did not similarly confer any sulfonamide resistance to folP-knockout bacteria. Nevertheless, sulfonamide resistance (MIC = 50?μM) of folP-knockout bacteria transformed with plasmid-encoded folP was much less than the resistance (MIC = 4?mM) expressed by chromosomally-encoded folP. Therefore, folP point mutations only partially explain bacterial resistance to sulfonamide. 1. Introduction Streptococcus mutans are commensal bacteria found in the oral cavity [1]. These bacteria which belong to the Viridans Streptococci Group (VSG) cause dental caries and infrequently give rise to extra oral infections like subacute bacterial endocarditis [1, 2]. Although dental caries is not usually treated by antibiotics, the VSG have attracted interest due to their potential to act as reservoirs of resistance to antibiotic determinants [3]. Additionally, in individuals taking antibiotics as prophylaxis, resistance of commensals to antibiotic determinants could be selected [4] and transferred to pathogenic organisms [5] such as Streptococcus pneumoniae which kills over 1,000,000 children worldwide every year [4]. Cotrimoxazole (SXT) is a combination drug (sulfamethoxazole plus trimethoprim) that is commonly used as prophylaxis in HIV/AIDS patients [6]. Sulfamethoxazole is a long-acting sulphonamide. In addition to wide usage as prophylaxis, SXT is also a highly prescribed drug especially in Sub-Saharan Africa due to its low cost and easy availability.
References
[1]
W. J. Loesche, “Role of streptococcus mutans in human dental decay,” Microbiological Reviews, vol. 50, no. 4, pp. 353–380, 1986.
[2]
R. Facklam, “What happened to the streptococci: overview of taxonomic and nomenclature changes,” Clinical Microbiology Reviews, vol. 15, no. 4, pp. 613–630, 2002.
[3]
A. Bryskier, “Viridans group streptococci: a reservoir of resistant bacteria in oral cavities,” Clinical Microbiology and Infection, vol. 8, no. 2, pp. 65–69, 2002.
[4]
M. Wilén, W. Buwembo, H. Sendagire, F. Kironde, and G. Swedberg, “Cotrimoxazole resistance of Streptococcus pneumoniae and commensal streptococci from Kampala, Uganda,” Scandinavian Journal of Infectious Diseases, vol. 41, no. 2, pp. 113–121, 2009.
[5]
P. Echave, J. Bille, C. Audet, I. Talla, B. Vaudaux, and M. Gehri, “Percentage, bacterial etiology and antibiotic susceptibility of acute respiratory infection and pneumonia among children in rural Senegal,” Journal of Tropical Pediatrics, vol. 49, no. 1, pp. 28–32, 2003.
[6]
A. Sosa, “Who issues guidelines on use of cotrimoxazole prophylaxis,” 2006, http://www.who.int/hiv/pub/guidelines/ctx/en/index.html.
[7]
B. William, C. M. Rwenyonyi, G. Swedberg, and F. Kironde, “Cotrimoxazole prophylaxis specifically selects for cotrimoxazole resistance in streptococcus mutans and Streptococcus sobrinus with varied polymorphisms in the target genes folA and folP,” International Journal of Microbiology, vol. 2012, Article ID 916129, 10 pages, 2012.
[8]
A. Kamulegeya, B. William, and C. M. Rwenyonyi, “Knowledge and antibiotics prescription pattern among ugandan oral health care providers: a cross-sectional survey,” Journal of Dental Research, Dental Clinics, Dental Prospects, vol. 5, no. 2, pp. 61–66, 2011, http://dentistry.tbzmed.ac.ir/joddd.
[9]
O. Skold, “Resistance to trimethoprim and sulfonamides,” Veterinary Research, vol. 32, no. 3-4, pp. 261–273, 2001.
[10]
D. Ajdi?, W. M. McShan, R. E. McLaughlin et al., “Genome sequence of streptococcus mutans UA159, a cariogenic dental pathogen,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, pp. 14434–14439, 2002.
[11]
F. Maruyama, M. Kobata, K. Kurokawa et al., “Comparative genomic analyses of streptococcus mutans provide insights into chromosomal shuffling and species-specific content,” BMC Genomics, vol. 10, article 358, 2009.
[12]
C. Yanisch-Perron, J. Vieira, and J. Messing, “Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors,” Gene, vol. 33, no. 1, pp. 103–119, 1985.
[13]
C. Fermér and G. Swedberg, “Adaptation to sulfonamide resistance in Neisseria meningitidis may have required compensatory changes to retain enzyme function: kinetic analysis of dihydropteroate synthases from N. meningitidis expressed in a knockout mutant of Escherichia coli,” Journal of Bacteriology, vol. 179, no. 3, pp. 831–837, 1997.
[14]
S. F. Altschul, W. Gish, W. Miller, E. W. Myers, and D. J. Lipman, “Basic local alignment search tool,” Journal of Molecular Biology, vol. 215, no. 3, pp. 403–410, 1990.
[15]
O. Sk?ld, “Sulfonamides and trimethoprim,” Expert review of anti-infective therapy, vol. 8, no. 1, pp. 1–6, 2010.
[16]
S. Sridaran, S. K. McClintock, L. M. Syphard, K. M. Herman, J. W. Barnwell, and V. Udhayakumar, “Anti-folAte drug resistance in Africa: meta-analysis of reported dihydrofolAte reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations,” Malaria Journal, vol. 9, no. 1, article 247, 2010.
[17]
M. Brochet, E. Couvé, M. Zouine, C. Poyart, and P. Glaser, “A naturally occurring gene amplification leading to sulfonamide and trimethoprim resistance in Streptococcus agalactiae,” Journal of Bacteriology, vol. 190, no. 2, pp. 672–680, 2008.